Oral anticoagulation therapy is useful for preventing stroke in patients with AF. However, several studies, including a meta-analysis, have shown that warfarin is not associated with a decrease in the rates of mortality and ischemic stroke but is associated with an increase in the risk of major bleeding in patients on dialysis who have AF (5) . According to the guideline established by the Japanese Society for Dialysis Therapy, the use of warfarin to prevent stroke is generally not recommended in patients on dialysis, and cautious use of warfarin with tight control of International Normalized Ratio (INR) <2.0 is only considerable in patients whose risk of stroke is estimated to be decreased by the drug.
In the last decade, direct non-vitamin K-dependent oral anticoagulants (DOACs) have become available for the prevention of stroke in patients with AF. However, phase III studies for DOACs have not included patients with endstage kidney disease, and DOACs are not recommended in patients on dialysis under the current guidelines. Still, some studies have examined the efficacy of DOACs in patients with end-stage kidney disease (6, 7) . In a meta-analysis, the incidence of ischemic stroke was found to be similar between DOACs and warfarin, and the incidence of major bleeding was slightly lower with DOACs than with warfarin in patients with [a reduced?] creatinine clearance or an estimated glomerular filtration rate between 15 and 60 mL/ min (6) . In other studies, the incidences of both stroke and bleeding were similar between apixaban and warfarin in patients with severe kidney dysfunction (7) . DOACs may be useful in patients with end-stage kidney disease, although further studies are needed to determine their efficacy and safety.
Although AF has little to no impact on the risk of stroke in patients on dialysis, AF is associated with adverse events (8) . AF is associated with all-cause mortality (hazard ratio, 1.32-1.82) and cardiovascular events (hazard ratio, 1.39-2.15) in patients on dialysis (8) . Interestingly, in a Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences, JapanIntern Med 57: 2285-2286, 2018 DOI: 10.2169/internalmedicine.0735-17 study on this issue, the incidence of non-cardiovascular death has seemed higher in patients with AF (103.0 per 1,000 patient years) than in those without AF (37.9 per 1,000 patient years), although AF was found to not be associated with the risk of non-cardiovascular death in another study (3, 8) . The presence of AF may indicate a poor prognosis in patients on dialysis.
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